Literature DB >> 25376487

The use of bisphosphonates in pediatrics.

Giampiero I Baroncelli1, Silvano Bertelloni.   

Abstract

Bisphosphonates are widely used for the prevention and treatment of osteoporosis in adulthood. In the last years, bisphosphonates have been increasingly used in pediatric patients for the treatment of a growing number of disorders associated with osteoporosis, resistant hypercalcemia or heterotopic calcifications. The use of bisphosphonates in pediatric patients has been proven safe; however, the risk of potential severe consequences into adulthood should be kept in mind. Well-defined criteria for bisphosphonates treatment in pediatric patients are not specified, therefore an accurate selection of patients who could benefit from bisphosphonates is mandatory. A strict follow-up of pediatric patients receiving long-term bisphosphonate therapy is strongly recommended. The purpose of this mini review is to provide a summary of current knowledge on some main general aspects of the structure, mechanisms of action, pharmacokinetics, and bioavailability of bisphosphonates, and to focus on the latest advances of bisphosphonate treatment in pediatric patients. Particular attention has been paid to the common and potential adverse effects of bisphosphonate treatment, and some suggestions concerning the clinical approach and general measures for bisphosphonate treatment in pediatric patients are reported. 2014 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25376487     DOI: 10.1159/000365889

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  14 in total

1.  Bisphosphonates: from softening water to treating PXE.

Authors:  Stephanie N Moore; S Bobo Tanner; Jonathan G Schoenecker
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  A toddler with severe hypercalcemia and pyelonephritis: Answers.

Authors:  Joseph Wilbanks; Jessica Hillyer; Faris Hashim; David Sas; Christian Hanna
Journal:  Pediatr Nephrol       Date:  2020-07-20       Impact factor: 3.714

Review 3.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

4.  Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study.

Authors:  Evelina Maines; Elisa Tadiotto; Grazia Morandi; Michela Fedrizzi; Rossella Gaudino; Paolo Cavarzere; Alessandra Guzzo; Franco Antoniazzi
Journal:  J Pediatr Genet       Date:  2020-01-06

5.  Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.

Authors:  Giampiero I Baroncelli; Elena Ferretti; Cecilia M Pini; Benedetta Toschi; Rita Consolini; Silvano Bertelloni
Journal:  Mol Syndromol       Date:  2017-09-09

6.  Osteoporotic Conditions Influence the Activity of Adipose-Derived Stem Cells.

Authors:  Jeong Seop Park; Jiyuan Piao; Gabee Park; Kyung Sang Yoo; Hyun Sook Hong
Journal:  Tissue Eng Regen Med       Date:  2020-09-18       Impact factor: 4.169

Review 7.  Prevalence of dental alterations in patients under bisphosphonates therapy: a systematic review.

Authors:  Monique Abreu Pauli; Natália Cristina Trentin Bordignon; Geórgia Ribeiro Martini; Mariana Comparotto Minamisako; Rogério Gondak
Journal:  Oral Maxillofac Surg       Date:  2022-06-04

Review 8.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

Review 9.  Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Jenneke E van Atteveld; Renée L Mulder; Marry M van den Heuvel-Eibrink; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; W Hamish Wallace; Louis S Constine; Claire E Higham; Sue C Kaste; Riitta Niinimäki; Sogol Mostoufi-Moab; Nathalie Alos; Danilo Fintini; Kimberly J Templeton; Leanne M Ward; Eva Frey; Roberto Franceschi; Vesna Pavasovic; Seth E Karol; Nadia L Amin; Lynda M Vrooman; Arja Harila-Saari; Charlotte Demoor-Goldschmidt; Robert D Murray; Edit Bardi; Maarten H Lequin; Maria Felicia Faienza; Olga Zaikova; Claire Berger; Stefano Mora; Kirsten K Ness; Sebastian J C M M Neggers; Saskia M F Pluijm; Jill H Simmons; Natascia Di Iorgi
Journal:  Lancet Diabetes Endocrinol       Date:  2021-07-30       Impact factor: 44.867

10.  A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia.

Authors:  Hye-Jin Park; Eun-Jin Choi; Jin-Kyung Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.